Login / Signup

Assessment of Different Infectious Bovine Rhinotracheitis Marker Vaccines in Calves.

Stefano PetriniAlessandra MartuccielloCecilia RighiGiovanna CappelliClaudia TorresiCarlo GrassiEleonora ScocciaGiulia CostantinoCristina CasciariRoberto SabatoMonica GiammarioliEsterina de CarloFrancesco Feliziani
Published in: Vaccines (2022)
Three commercially available infectious bovine rhinotracheitis (IBR) live marker vaccines were evaluated for their ability to provide clinical protection to vaccinated calves against wild-type (wt) Bovine alphaherpesvirus-1 (BoHV-1) challenge and their possible effect on wt BoHV-1 latency reactivation following the challenge. On 35 post-vaccination days (PVDs), all animals were challenged with wt BoHV-1. Only the calves in the control group developed severe forms of IBR. The reactivation of latent BoHV-1 was induced by dexamethasone (DMS) treatment on 28 post-challenge days (PCDs). All animals showed IBR clinical signs on three post-DMS treatment days (PDTDs). On PVD 14, all vaccinated animals developed neutralizing antibodies (NAs), whereas in control animals, the NAs appeared post-challenge. The positivity for glycoprotein-B (gB) was detected using real-time polymerase chain reactions in all animals from PCDs 1 to 7. In contrast, the gB-positivity was observed in the immunized calves from PDTDs 3 to 10. Positive expression of gD and gE was observed in nasal swabs of all calves on PDTD 7. These findings suggested that the IBR marker vaccines evaluated in this study protected against wt BoHV-1-induced disease but not against wt BoHV-1-induced latency reactivation, indicating the necessity of developing new products to protect animals from wt BoHV-1-induced latency.
Keyphrases
  • high glucose
  • diabetic rats
  • drug induced
  • poor prognosis
  • oxidative stress
  • computed tomography
  • low dose
  • combination therapy
  • contrast enhanced